ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib

pharmanewsdaily- November 23, 2019 0

ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase ... Read More